Compare Recursion Pharmaceuticals Inc (RXRX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Weibo Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $4.09 (market cap $2.14B), while Weibo Corp trades at $6.54 (market cap $1.56B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Weibo Corp pays a 9.47% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Weibo Corp for 102 Days on average.
| RXRX | WB | |
|---|---|---|
Market Cap | $2.14B | $1.56B |
Volume | 30,789,535 | 812,503 |
Sector | Health | Media |
52-Week High | $6.79 | $12.37 |
52-Week Low | $2.84 | $6.33 |
Typical Hold Time | 22 Days | 102 Days |
Enterprise Value | $1.66B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Weibo (WB) trades at $6.55, up 1.08% on the day, with a bearish technical signal. The stock is fundamentally attractive with a low P/E of 5.32 and P/B of 0.4, while profitability remains solid with a net income margin of 17.78%. Recent Q2 2026 earnings beat expectations, though revenue growth is modest. Cash flow trends show volatility, with a significant net outflow in 2024.
The outlook is mixed; deep-value metrics and strong cash generation offer upside, but declining user metrics and advertising headwinds pose risks. Analyst consensus is divided, leaning slightly toward Hold. The stock presents a value opportunity for patient investors, contingent on stabilizing user engagement and advertising demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
